A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer by A. Esposito et al.
PERSPECTIVE
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+
breast cancer
Angela Espositoa, Giulia Vialea,b, Carmen Criscitielloa and Giuseppe Curiglianoa,b
a5 Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology, IRCCS MilanoAQ1 �; bDepartment of Oncology and
Hemato-Oncology, University of Milano
ABSTRACT
Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic
therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer
10 is chemotherapy plus trastuzumab administered for 1 year.
Areas covered: Several trials have investigated modifications of the standard treatment in terms of de-
escalation by either shortening the duration or giving less resource-demanding regimens and in terms
of escalation by either adding a second anti-HER2 agent or extending the duration of HER2-targeted
treatment for more than 12 months. In this perspective, we would offer a comprehensive view of these
15 trials and discuss their findings.
Expert commentary: At the current state of knowledge, there are still open questions regarding the
management of HER2+ BC patients, such as the most adequate duration of trastuzumab therapy, the
optimal chemotherapy regimen that should be combined with trastuzumab, and the addition of
a second anti-HER2 agent. Growing evidences suggest that some HER2+ BC patients may not need
20 chemotherapy. If these patients could be recognized upfront, optimal response could potentially be
reached with HER2-targeted therapy alone.
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1. Introduction
The human epidermal growth factor receptor 2 (HER2) has
25 been shown to be overexpressed in 15% of breast cancers
(BC) [1]. Overexpression of HER2 in BC seems to confer a more
aggressive phenotype and, historically, was correlated with
a poor prognosis with lower disease-free survival (DFS) and
overall survival (OS) rates, higher risk of recurrence and greater
30 resistance to therapy [2–4]. Patients with early HER2-positive
BC benefit from HER2-targeted systemic therapy. The
endorsed standard adjuvant treatment for patients with early
HER2-positive BC is chemotherapy plus trastuzumab adminis-
tered for 1 year.
35 Trastuzumab has dramatically changed the natural course
of HER2 positive BC, transforming an aggressive subtype of
breast cancer in one that may achieve an excellent prognosis
[5–8]. Adjuvant trastuzumab was first investigated in four large
randomized trials: the National Surgical Adjuvant Breast and
40 Bowel Project (NSABP) trial B-31, the North Central Cancer
Treatment Group (NCCTG) trial N9831, the HERceptin
Adjuvant trial (HERA), and the Breast Cancer International
Research Group (BCIRG) trial 006 [9–11]. The same trastuzu-
mab dose and the same duration (12 months) were selected
45 for evaluation in all four trials; however, the original decision
to give trastuzumab for 1 year was arbitrary and not sup-
ported by preclinical nor clinical data [12]. In 2006, the Food
and Drug administration (FDA) approved the use of trastuzu-
mab in the adjuvant setting of BC. In the absence of data from
50other schedules, the 1 year duration became the standard.
Updated results of the adjuvant trastuzumab trials, with
8 years [13] and 10 years of median follow up, showed con-
sistent disease-free survival (DFS) and overall survival (OS)
benefits with the addition of trastuzumab to chemotherapy
55[14,15]. These data were particularly relevant because investi-
gators of all trials, with the exception of BCIRG006, allowed
crossover to trastuzumab for patients enrolled in the control
groups of the studies. In addition, the HERA trial has confirmed
that 24 months treatment does not further improve DFS and
60OS [16].The current standard treatment is costly, lengthy and
occasionally associated with cardiac adverse events, which
occurred in less than 3% of patients treated in the pivotal
clinical trials. In the last years, other studies investigated mod-
ifications of the schedule of treatment with trastuzumab by
65either making it shorter and less toxic (de-escalation), or more
effective with dual HER2 inhibition or extended treatment
duration (escalation) (Table 1).
2. De-escalation trials
Seven randomized trials address the topic whether a shorter
70regimen of adjuvant trastuzumab may be as effective as 1-year
of trastuzumab, but with fewer side-effects.
In four of these trials, trastuzumab is given concomitantly with
chemotherapy in the experimental armwith the aim to investigate
drug synergism (FinHer, E2198, SOLD, and Short-HER trials), and
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75 three trials compare 6-month to 12-month duration of trastuzu-
mab (the Hellenic trial, PHARE, and PERSEPHONE) [8,17–25].
In the FinHer study [8], 1010 women with axillary node-
positive or high-risk node-negative breast cancer were rando-
mized to receive three cycles of docetaxel or vinorelbine, fol-
80 lowed in both groups by three cycles of fluorouracil (F),
epirubicin (E), and cyclophosphamide (C). Patients with HER2-
positive breast cancer (n = 232) were further treated with
trastuzumab or no additional therapy. Even with the shorter
duration of trastuzumab after a median follow-up of 8 years,
85 distant DFS (83.3% vs 73%) and OS (91.3% vs 82.3%) favored the
trastuzumab arm, but the difference in OS was not statistically
significant. The trial showed a benefit, although this was a small
trial, and the docetaxel dose was 100 mg/m2 in about a half of
patients, while now many patients receive a smaller dose [8].
90 In SOLD trial [19], 2,176 patients with early-stage HER2-
positive BC were randomized (1:1) to the 9-week trastuzumab
arm or the 12-month trastuzumab arm. Patients in both arms
received three cycles of docetaxel (80 mg/m2 or 100 mg/m2)
and trastuzumab three times a week, followed by three cycles
95 of chemotherapy. Patients in the 9-week arm received no
further treatment, whereas those in the 12-month arm
received trastuzumab every 3 weeks for 14 cycles. The trial
failed to demonstrate that 9 weeks of adjuvant trastuzumab
were not inferior to the standard 12 months in terms of DFS
100 [19].The 5-years estimated DFS rate was 90.5% with 1 year of
trastuzumab versus 88.0% with 9 weeks (HR, 1.39; 90% CI,
1.12–1.72). The 5-year estimated OS rates were 95.9% versus
94.7%, respectively (HR, 1.36; 90% CI, 0.98–1.89). The esti-
mated 5-year rate of patients without distant recurrence (dis-
105 tant-free survival) was also higher with longer trastuzumab at
94.2% compared with 93.2%, respectively (HR, 1.24; 90% CI,
0.93–1.65).The shorter trastuzumab treatment was safer to the
heart than the longer treatment. In the 9-week group there
have been 22 protocol-defined cardiac adverse events
110compared with 42 in patients receiving 1 year of trastuzumab
(p = .012). Congestive heart failure occurred in 21 and 36
patients in the 2 arms, respectively (p = .046). Due to cancer
characteristics (many patients had node-negative cancer and
some investigators preferred not to enroll patients with a high
115risk of cancer recurrence) and some logistical issues, the
planned number of DFS events was not reached within
a reasonable period; hence, the study had lower statistical
power than planned, thus limiting the interpretation of the
results.
120In the Short-HER study [20,26], patients were randomly
selected to receive 1 year of trastuzumab plus chemotherapy
(‘long’ group) or 9 weeks of trastuzumab plus chemotherapy
(‘short’ group). The primary endpoints were DFS and OS.
Secondary endpoints included failure rate at 2 years and the
125incidence of cardiac events. The 5-year DFS did was not non-
inferior in the frequentist analysis (87.5% vs. 85.4% in the long
and short groups, respectively, hazard ratio [HR] 1.15, 90% CI
[0.91, 1.46]). In an analysis of DFS in patients with earlier-stage
disease (stage I and II) as compared to those with locally
130advanced disease (stage III), the shortened duration was not
inferior to the longer one. There was no difference in OS at
5 years. There was an ongoing decline in left ventricular ejection
fraction for the long group. Therefore, patients with stage III
disease and multiple positive lymph nodes may derive greater
135benefit from a longer duration of trastuzumab, while a selected
group of patients who cannot tolerate 12months of therapymay
be reasonably treated with a shorter duration [26]. The open-
label randomized phase III PHARE trial [22] randomized 3384
patients with HER2-positive early BC who had received at least
140four cycles of chemotherapy and up to 6 months of adjuvant
trastuzumab to either continue trastuzumab for another
6 months or to stop trastuzumab at 6 months. After 3.5 years
of follow-up, 175 DFS events occurred in patients assigned to
12 months of trastuzumab compared with 219 events in the
Table 1. Summary of results of major trials addressing the lenght of adjuvant trastuzumab.
Study Number of patients/years of follow up Regimens DFS/DDFS Overall Survival
FinHer [8] 116; 5.2 years D/Vix3 + T9 wk→FECx3
D/Vix3→FECx3
83.3%
73.0%
HR 0.65
91.3%
82.3%
HR 0.55
SOLD [19] 2136;5 years Dx3 + T9 wk→FECx3→T42 wk
Dx3 + T9wk→FECx3
88.0%
90.5%
HR 1.39
94.7%,
95.9%
HR 1.36
Short-HER [20,26] 1200; 5 years AC/ECx4→D/Px4 + T12 wk→T42 wk
Dx3 + T9 wk→FECx3
85.4%
87.5% vs. in HR 1.15
95.1%
95.0%
HR 1.06
PHARE trial [22] 3384; 3.5 years Chemotherapy ≥ 4 cycles→T12 mo
Chemotherapy ≥ 4 cycles→T6 mo
2-y 93.8%
2-y 91.1%
HR 1.28
NA
Persephone [24,25] 4,088; 5 years Chemotherapy→T 12 mo
Chemotherapy→T 6 mo
89.8%
89.4%
HR 1.29
94.8%
93.8%
HR 1.14
HERA [11] 5099; 8 years Chemotherapy x4 cycles→T12 mo
Chemotherapy x4 cycles→T24 mo
81%
82%
HR 0.99
88%
86%
HR 1.05
EXTEnet [35] 2840; 2.3 years Chemotherapy x4 cycles→T12 mo
Chemotherapy x4 cycles→T12 mo→N12 mo
87.7%
90.2%
NA
ALTTO [38,39] 8381; 4.5 years PT x12w→T x40w
PL x12 w→ L x40w (closed)
PT x12w→L x34w
PTL x12 w→TL x40w
88% (L + T)
86% (T)
HR 0.84
95% (L + T)
94% (T)
HR 0.80
DFS: disease-free survival; T: trastuzumab; D: docetaxel; P:paclitaxel;Vi: vinorelbine; L: lapatinib; FEC; fluorouracil, epirubicin, cyclophosphamide; HR: hazard ratio; wP:
weekly paclitaxel; AC: doxorubicin plus cyclophosphamide; N.A.: not available; EC: epirubicin plus cyclophosphamide; P: paclitaxel; N:neratinib,
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145 6-month group. Data indicated that the 2-year DFS was 93.8% for
patients assigned to the standard of care as compared to 91.1%
for the 6-month regimen (HR = 1.28; 95% CI, 1.01–1.56; p = .29).
A greater percentage of patients assigned to 12 months of
treatment experienced cardiac events compared with patients
150 assigned to 6-month treatment (5.7% of patients vs 1.9%;
p < .0001). Despite the increased rate of cardiac events that
occurred in patients assigned to 12-month treatment, the
researchers concluded that the longer regimen should remain
the standard of care [22].
155 Persephone is a randomized phase III non-inferiority trial com-
paring 6 months of trastuzumab to the standard 12 months in
4,088 patients enrolled from 152 sites in the United Kingdom
between 2007 and 2015 [24,25]. Patients received standard che-
motherapy regimens asper institutional practice as either adjuvant
160 chemotherapy or neoadjuvant chemotherapy, and either concur-
rently with or sequentially to trastuzumab, and trastuzumab for
either 6 or 12months based on random allocation. Randomization
occurred before the 10th cycle of trastuzumab. At amedian follow-
up of 5 years, the researchers found near-identical results between
165 the two treatment arms: DFS was 89.4% among women in the
6-month arm and 89.8% among women in the 12-month arm
(hazard ratio, 1.29). Only 4% of women who received trastuzumab
for 6 months stopped treatment early due to heart problems,
compared to 8% of those who received trastuzumab for
170 12 months. The study results demonstrate that 6 months of tras-
tuzumab is non-inferior to 12 months. A pre-defined sub group
analysis revealed thatgroupsmore likely tobenefit from12months
of trastuzumab therapy compared to 6 months included those
patients who received trastuzumab concurrently with chemother-
175 apy, patients who received neoadjuvant chemotherapy, those
who received taxanes and among patients who had ER negative
disease. The investigators emphasized that—although a few other
studies have evaluated shorter durations of trastuzumab—
Persephone is the largest non-inferiority trial. Ongoing research is
180 evaluating quality-of-life and patient-reported outcomes in this
population. Important translational research will be carried out
analyzing blood and tumor samples to look for biomarkers to
identify subgroups of different risk where shorter/longer durations
of trastuzumab might be tailored.
185 Besides the duration and timing of trastuzumab therapy,
the drugs combined to trastuzumab changed across the trials.
Hypothetically, the duration of trastuzumab administration
might become relatively less meaningful as the efficacy of
the drug combinations augments.
190 The timing of randomization also varied. While in the FinHer,
E2198, SOLD, and theHellenic trial randomizationoccurredprior to
beginning systemic therapy; randomization was done after finish-
ing chemotherapy in PHARE, and prior to the 10th trastuzumab
cycle in PERSEPHONE. The timing of randomization may affect the
195 study patient populations, as patientswhoprogress rapidly orwho
do not tolerate therapy are excluded when randomization is done
after chemotherapy.
Besides shortening duration of adjuvant treatment, de-
escalation strategies also include a reduction of chemotherapy
200 or the use of less toxic agents instead of chemotherapy.
The BCIRG006 trial [9,14] of the Breast Cancer International
Research Group evaluated a non- anthracycline regimen with
docetaxel and carboplatin plus trastuzumab for a total of
52 weeks (TCH regimen) and compared it to a standard
205anthracycline and taxane containing chemotherapy ± trastu-
zumab (AC→T and AC-TH, respectively). The TCH regimen
resulted in significantly fewer cardiac events with a small
difference in estimated DFS compared to AC-TH at 10.3 years
of follow up (DFS 74 · 6% vs 73%; OS 85 · 9% vs 83 · 3%,
210respectively). The BCIRG006 trial, which included also patients
with small tumors (40% were pT1) and no axillary involvement
(28%), showed the benefit of the addition of trastuzumab to
chemotherapy even in a low-risk population; a metanalysis by
O’Sullivan et al. confirmed these results [27].
215However, in this low-risk population, a possible strategy to
spare toxicity might be the reduction of chemotherapy while
maintaining trastuzumab administration for one year, as sug-
gested by the APT trial [28]. This single arm prospective study
investigated a regimen with weekly paclitaxel and trastuzumab
220for 12 weeks, followed by 9 months of trastuzumab monother-
apy in women with small HER2-positive tumors, predominantly
stage I. At 4-year follow-up, DFS was 98.7%, with excellent toler-
ability. These results are also in line with data reported by
a recent observational study from the Netherlands [29]. Some
225studies are also evaluating to target the HER2 receptor with new
drugs and combinations. The phase II ATEMPT trial [30] rando-
mizes patients with stage I HER2-positive breast cancer to receive
either T-DM1 or paclitaxel in combination with trastuzumab,
followed by 1 year of trastuzumab to evaluate the possible
230omission of chemotherapy with taxane in this population. In
the same direction of de-escalating treatment, the phase II
ATOP trial [31] evaluates the role of T-DM1 in treating older
patients with stage I-III HER2 positive BC, who decline or are
not candidates to standard chemotherapy.
2353. Escalation trials
A 2008 meta-analysis including HERA, NCCTG-N9831, NSABP-
B31, BIRCG-006, FinHER, and PACS-04 trials assessed the ben-
efit of adjuvant trastuzumab, showing a mean decrease in risk
recurrence of about 37% and in risk mortality of about 34%
240[32]. The question addressed in subsequent clinical trials in
this setting is whether we could do any better.
The optimal duration of adjuvant trastuzumab treatment
remains 1 year. The HERA trial evaluated length of therapy,
comparing an observational arm with no trastuzumab,
245a 1-year trastuzumab arm and a 2-year trastuzumab arm [11].
At a median 8-year follow-up, no difference in DFS was
observed in patients treated with adjuvant trastuzumab for 1
or 2 years (HR, 0.99; 95% CI, 0.85–1.14; p = .86), while there
was an increased rate of grade 3/4 adverse events and higher
250cardiac toxicity (4.1% and 7.2% for the 1-year and 2-year
groups, respectively) [16,33]. Another phase III randomized
study, the EXTENET trial, evaluated one year of HER2-
targeted therapy with neratinib versus placebo in 2840
patients who had completed one year of trastuzumab for
255early stage disease [34]. In addition, to investigate a new
potential effective drug in the adjuvant setting, this study
also evaluates 2 years of adjuvant HER2-targeted treatment.
A prespecified early analysis at the 2-year mark showed an
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improved DFS in patients receiving neratinib, especially in
260 case of hormone receptor co-expressing cancer(HR 0 · 51,
95% CI 0 · 33–0 · 77; p = 0 · 0013) .At 2-year follow-up, invasive
DFS was 93.9% for neratinib arm compared to 91.6% for the
control arm; subsequent data showed a 5-year invasive DFS of
90.2% in the neratinib group compared to 87.7% in the pla-
265 cebo group [35]. This benefit was counterbalanced by a severe
gastrointestinal toxicity, with 40% of patients reporting grade
3 diarrhea, leading to dose reductions in 26% and treatment
discontinuation in 17% of the patients [34]. Notably, at the
time of ExteNET study design, management of diarrhoea was
270 instituted only after the development of symptoms. Studies
exploring different strategies for gastrointestinal toxicity,
including the use of prophylactic loperamide, are under inves-
tigation. At SABCS 2017 were presented the initial data of
CONTROL trial. In this trial, patients with HER2-positive early
275 stage breast cancer who had completed trastuzumab-based
adjuvant therapy received neratinib daily for a period of
one year + oral loperamide prophylaxis for one or two cycles
(1 cycle = 28 days) ± budesonide or colestipol for the first
cycle. The results showed that a structured loperamide pro-
280 phylactic regimen for 1 or 2 cycles reduces the incidence,
severity and duration of neratinib-associated diarrhea com-
pared with events observed in the ExteNET trial. Adding bude-
sonide or colestipol appears to further diminish the duration
and number of episodes of diarrhea and improves neratinib
285 tolerability [36].Based on the results of ExteNET trial, the FDA
approved neratinib for patients with early-stage HER2 positive
breast cancer who have finished 1 year of adjuvant trastuzu-
mab. The European Committee for Medicinal Products for
Human Use (CHMP) adopted a positive opinion recommend-
290 ing marketing authorization for neratinib in June 2018, after
an initial negative opinion; however, it concluded that benefits
seemed to be largely confined to patients with hormone-
receptor positive cancer [37].
Indeed, given the lack of OS data, the not clinically and
295 statistically significant 1.7% improvement in distant DFS at
5 years in the entire population, the gastrointestinal toxicity
and the cost, extended adjuvant neratinib should not be
recommended to all patients. However, it should be discussed,
especially in the high-risk population, with locally advanced
300 HER2-positive, estrogen receptor-positive breast cancer, many
positive nodes or residual disease after neoadjuvant therapy.
Important amendments were instituted during the course
of the trial. With the acknowledgement that patients with
node-negative disease have a good prognosis with standard
305 chemotherapy/trastuzumab treatment, eligibility was limited
to patients with node-positive disease, but only after 671
patients with node-negative cancer had been enrolled. This
represented 24% of the patients in the final intent-to-treat
analysis, and their inclusion may have restricted slightly the
310 difference between the investigational and control groups.
Another important amendment was to reduce the allowed
interval between completion of trastuzumab and enrollment
from 2 years to 1 year, thereby capturing patients who might
have experienced a recurrence during the second year off
315 therapy. Given these considerations, a 2.3% absolute improve-
ment in invasive disease-free survival is evidence of the
activity of neratinib in this population, especially in patients
with higher risk disease.
Another oral tyrosin kinase inhibitor, lapatinib, has been
320investigated in the adjuvant setting alone (as in TEACH trial
[38]), or in addition to trastuzumab. The ALTTO trial (Adjuvant
Lapatinib and/or Trastuzumab Treatment Optimization) [39,40]
compared a year of adjuvant trastuzumab to a year of lapati-
nib, but also evaluated a sequential strategy (12 weeks of
325trastuzumab followed by 34 weeks of lapatinib) and a combi-
nation approach with dual HER2 targeting (trastuzumab plus
lapatinib for 52 weeks). The study was conducted between
2007 and 2011 and enrolled 8,381 patients. In 2011, after an
interim analysis, the lapatinib monotherapy arm was closed for
330futility to demonstrate non-inferiority of lapatinib versus tras-
tuzumab. At a protocol-specified analysis with a median fol-
low-up of 4.5 years, the combination of trastuzumab and
lapatinib was not shown to significantly improve DFS com-
pared with trastuzumab alone (HR, 0.84; 95% CI, 0.70–1.02;
335p = .048), nor the sequential strategy provided a benefit over
trastuzumab (HR, 0.96; 95% CI, 0.80–1.15; p = .61). Moreover,
lapatinib was associated with lower rates of completion of
HER2-targeted therapy, due to its notable toxicity profile (lapa-
tinib led to higher rates of diarrhea, cutaneous rash, and
340hepatic toxicity were observed, whereas cardiac toxicity was
low in all treatment arms) [40].
The addition of bevacizumab to anthracycline and non-
anthracycline (TCH) adjuvant trastuzumab regimens was inves-
tigated in the phase III BETH trial [41] This study randomized
3453509 patients to receive a total of one year adjuvant trastuzu-
mab alone or in combination to bevacizumab following che-
motherapy. At a median follow-up of 38 months, the invasive
DFS rates were 92% for both groups and no significant differ-
ence in efficacy between the bevacizumab and no-
350bevacizumab regimens was observed, despite additional toxi-
city in the bevacizumab arms. Thus, this strategy has not been
further explored.
Pertuzumab—a recombinant humanized monoclonal anti-
body that targets the extracellular dimerization domain of
355HER2—has been recently approved by FDA and EMA as adju-
vant therapy for early stage HER2 positive high-risk (estrogen
receptor negative and node positive) breast cancer in combi-
nation with chemotherapy and trastuzumab for one year (up
to 18 cycles). The approval was obtained based on the results
360of the phase III randomized APHINITY trial [42], which evalu-
ated efficacy and safety of the addition of pertuzumab to
adjuvant trastuzumab and chemotherapy in 4805 patients
with early HER2-positive breast cancer. Patients with tumors
smaller than 1 cm were excluded; overall 63% of patients had
365node-positive disease, and 36% had hormone receptors nega-
tive disease. At an early follow-up of 3 years, the rate of
invasive DFS was 94.1% in the pertuzumab group and 93.2%
in the placebo group. When evaluating results by nodal status,
the benefit was greater in patients with node-positive disease
370(invasive- DFS was 92.0% in the pertuzumab group, as com-
pared with 90.2% in the placebo group). A treatment effect
was most detectable among patients who were at higher risk
for hormone-receptor negativity (invasive-DFS was 92.8% in
the pertuzumab group and 91.2% in the placebo group), but
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375 the effect was statistically homogeneous throughout all
subgroups.
Trastuzumab emtansine (T-DM1) is an antibody-drug con-
jugate already approved in the metastatic setting that is under
evaluation also in early HER2 positive BC. Several trials inves-
380 tigating the role of T-DM1 as adjuvant therapy are ongoing, in
addition to the ones already mentioned above. The phase III
KATHERINE study investigates the use of adjuvant T-DM1
(compared to trastuzumab) in patients with residual disease
after neoadjuvant therapy [43], the data will be presented at
385 the 2018 San Antonio Breast Cancer Symposium. The phase III
KAITLIN trial compares adjuvant T-DM1 plus pertuzumab to
trastuzumab, pertuzumab, and a taxane (weekly paclitaxel or
docetaxel), each given after anthracyclines and the results are
still awaited [44].
390 4. Conclusions
Since the development of trastuzumab, several drugs, antibo-
dies, antibody-drug conjugates, and tyrosine kinase inhibitors
have become part of the useful arsenal for the treatment of
HER2-positive BC. Until now, the overall strategy has escalated
395 the treatment by combining more HER2-targeted agents.
However, the treatment escalation is encumbered by high
cost and significant toxicity, and in some cases might be an
overtreatment. Therefore, redesigning the current treatment stra-
tegies is crucial andde-escalation is a research priority to diminish
400 adverse effects without compromising patient outcome.
5. Expert commentary
At the current state of knowledge, there are still open ques-
tions regarding the management of HER2+ BC patients, such
as the most adequate duration of trastuzumab therapy, the
405 optimal chemotherapy regimen that should be combined with
trastuzumab, and the addition of a second anti-HER2 agent.
Growing evidences suggest that some HER2+ BC patients may
not need chemotherapy [28].
If these patients could be recognized upfront, optimal
410 response could potentially be reached with HER2-targeted
therapy alone. On the other hand, tumors that do not take
advantage from this approach may be treated with che-
motherapy or other strategies to overcome resistance.
Translational research is underway to look for biomarkers of
415 risk recurrence, which could help determining the optimal
trastuzumab therapy for each patient and identifying different
risk groups.
Although many biomarkers are under evaluation, no one is
already able to guide patient selection for best trastuzumab
420 therapy. A meta-analysis conducted by Loibl et al. [45] shows
a lower rate of pathologic complete response (pCR) in pre-
sence of a PIK3CA mutation, which may confer resistance to
anti-HER2 therapy; however, this difference in pCR does not
translate into a DFS difference. These results suggest that
425 although those patients without a PIK3CA mutation may
obtain higher pCR rates than those with a mutation, the
mutation is not predictive of long-term outcomes and thus
cannot be informative of patient selection. Also, data on the
predictive role of tumor infiltrating lymphocytes (TILs) in
430patients receiving anti HER2 therapy are discordant [46,47]
and further work must be done to evaluate whether patients
with high TILs may have similar outcomes with less che-
motherapy, and whether substituting chemotherapy with
immunotherapy may be favorable for these patients.
435Consideration of de-escalation therapy is also warranted for
the group of patients who obtains a pCR after preoperative
therapy. Results of a pooled analysis of 12 trials (11,955
patients) showed that patients with HER2-positive breast can-
cer who achieve a pCR have better long-term outcomes, with
440improved DFS and OS [48]. However, considering the lack of
association between treatment effects and long-term out-
comes, randomized trials with long-term follow up are
required to understand outcomes for specific therapies. Not
less important is the identification of mechanisms of resistance
445and data from neoadjuvant trials could be useful to discover
key determinants of response and resistance to anti HER2
therapy.
6. Five-year view
In the next years, it will be necessary a different therapeutic
450approach based on new predictive tools that allow an accu-
rate identification and stratification of patients according to
the risk. The launch of new clinical trials with the aim to
select patients on the base of these multi-parameter mole-
cular predictors should be considered in the neoadjuvant
455setting. Neoadjuvant treatment is currently recommended
and frequently used in clinical practice in patients with
HER2-positive operable breast cancer. Several trials, includ-
ing NeoSphere [49], TRYPHAENA [50] and GeparSepto stu-
dies [51] showed the benefit of combining chemotherapy
460with dual anti-HER2 directed treatment with pertuzumab
and trastuzumab. This approach has led to increased pCR
rates with no new or long term safety concerns. Of interest,
in many neoadjuvant trials, the possibility to de-escalate
treatment with chemo-free regimens has been explored.
465The largest reported trial of dual HER2-targeted neoadjuvant
therapy without concurrent chemotherapy is the PAMELA
study, in which 151 patients received trastuzumab and lapa-
tinib with possibly concomitant endocrine treatment accord-
ing to tumor subtype and showed [52]. The chemo-free
470combination in the PAMELA study led to a pCR rate of
30% [52] and similar results were obtained in TBCRC006
[53] and TBCRC023 [54] trials investigating the same regi-
men. In the NeoSphere trial, 107 patients were treated with
trastuzumab and pertuzumab without chemotherapy with
475some benefit (pCR rate 27% in HER2 positive/hormone
receptors negative breast cancer patients), albeit superior
results were observed for patients treated with concurrent
chemotherapy [49]. Similarly, the addition of taxane mono-
therapy to dual HER2 blockade substantially increased pCR
480rates in HER2positive/hormone receptors negative breast
cancer patients compared with dual blockade alone in the
WSG-ADAPT trial [55]. The possible use of TDM1 plus pertu-
zumab in the neoadjuvant setting was explored in the
KRISTINE/TRIO-021 trial, but again the efficacy was inferior
485to standard treatment [56].
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Thus, despite the combination of chemotherapy and dual
anti-HER2 directed treatment provided the highest rate of pCR
across trials and still remain the standard of care, nonchemother-
apy combinations of HER2-targeted therapy could represent
490 a possible option in those patients with health issues that pre-
clude the use of chemotherapy. However these results further
support the convenience to use of neoadjuvant study design to
investigate the topic. Indeed, the pCR rate seems to be a valid
surrogate marker of long-term outcome, mainly for HER2-
495 positive breast cancer [48]. Furthermore, the neoadjuvant setting
allows performing serial biopsies and in vivo molecular analyses
that are critical to assess for novel markers of response or resis-
tance to therapy. Since neoadjuvant trials are not always pow-
ered to evaluate long-term outcomes, adjuvant studies are still
500 needed to validate promising findings from the neoadjuvant
setting. In addition, despite the progresses in the treatment of
HER2 positive BC many patients still die, calling for the identifica-
tion of newer and better therapies. It could be interesting testing
the combinations with PI3K inhibitors, mTOR-targeting agents,
505 CDK4 and CDK6 inhibitors, or immunotherapies (eg, anti-PD-L1
antibodies), which would increase the likelihood of developing
effective treatments.
Key issues
● The advent of anti-HER2 therapies has changed the prog-
510 nosis of HER2-overexpressing breast cancer.
● The current standard adjuvant treatment for patients with
early HER2-positive breast cancer is chemotherapy plus
trastuzumab administered for 1 year but it is costly, lengthy,
and occasionally associated with cardiac toxicity.
515 ● Several trials have investigated modifications to the stan-
dard treatment: de-escalation and escalation regimens.
● The actual strategy is to escalate treatment by combining
more HER2-targeted agents.
However, the treatment escalation is encumbered by high cost
520 and significant toxicity. De-escalation strategy, which can be
achieved by either reducing or eliminating chemotherapy, could
be useful to mitigate the adverse effects without influencing
patient outcome.
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